To evaluate the efficacy and in vivo dynamics of general-purpose CAR-γδT cells in the treatment of refractory relapsed AML patients, and to explore the appropriate therapeutic dose and delivery mode.
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory post-transplant relapsed AML.